Recent clinical studies have demonstrated that CD33 is expressed at relatively high levels on leukemic blasts in patients with FLT3-mutated AML, providing a biological rationale for the integration of GO into existing treatment regimens. The gene discussed is FLT3; the disease is acute myeloid leukemia.